戻る Agenda
Session 2: Biosimilars During a Pandemic
Session Chair(s)
Laura McKinley, PhD
Director, Global Regulatory Policy and Intelligence
Pfizer Inc, United States
As the world continues to navigate the COVID-19 pandemic what will the impact be to biosimilars? This session will discuss the ways biosimilar stakeholders are adjusting to the COVID-19 pandemic to navigate and execute in the new normal. Panelists will present the regulatory perspectives, customer view, and potential impacts to access and uptake.
Learning Objective : At the conclusion of this session, participants should be able to:
- Recognize the short and long-term regulatory impacts of COVID-19 on biosimilar development and approvals
- Discuss the customer perspective of pandemic implications to biosimilar use
- Debate the short and long-term impacts of COVID-19 on access and uptake
Speaker(s)
Speaker
Peter P. Stein, MD
FDA, United States
Director, Office of New Drugs, CDER
Speaker
Sean McGowan, MBA
AmerisourceBergen, United States
Senior Director, Biosimilars
Speaker
Juliana Marguerite Reed, MS
The Biosimilars Forum, United States
Executive Director